-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
What is the overall survival rate of patients with advanced non-small cell lung cancer ( NSCLC ) who have failed previous treatment after receiving nivolumab treatment in the real world? A study published the results and found that the results of the real-world study were similar to those of the Phase III clinical trial.
NSCLC
Metastatic NSCLC progresses during or after platinum-containing chemotherapy, and immune checkpoint inhibitors have become standard treatments
immunity
The results showed that a total of 2585 patients were included, and 1235 (47.
The 1-year and 2-year overall survival rates of the total population were 49% and 28%, respectively
Original source:
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M.
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M.
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A Analysis of the pooled-World Real patients from France, Germany, and Canada.
Lung Cancer Jul-2021; 157:.
.
40-47 DOI: 10.
1016 / j.
lungcan.
2021.
04.
022
in this message
